Work

P2.13-43 Phase 1 Study of the Anti-HER3 Antibody Drug Conjugate U3-1402 in Metastatic or Unresectable EGFR-Mutant NSCLC

Year: 2018

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2018.08.1438

Authors: P. Jänne, H. Yu, M. Johnson, C. Steuer, M. Vigliotti, N. Shipitofsky, F.M. Guevara, S. Chen, C. Yu

Institutions: Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Memorial Sloan Kettering Cancer Center, Sarah Cannon, Winship Cancer Institute, Daiichi Sankyo (United States)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4243392903

FWCI:

Cites:

Cited by:

Related to: 10